Lucius LuciLenacap Lenacapavir 300mg

Product Information

• Product name: LuciLenacap Lenacapavir 300mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Lenacapavir
• Current strength: 300mg
• SKU: LU-ITEM-4
• Site category: AIDS, other cancer

Product Summary

LuciLenacap Lenacapavir 300mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Lenacapavir is the active ingredient used for this product page. Public prescribing information for Lenacapavir was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Lenacapavir is an HIV-1 antiretroviral agent with long-acting properties .

Reference Indications

Lenacapavir is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating Lenacapavir . Lenacapavir, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating Lenacapavir.

Reference Dosage and Administration

Taken without regard to food.

Dose conversion must be confirmed by a physician because the reference dose may vary by indication, organ function, toxicity, or interacting medicines.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

WARNING: RISK OF DRUG RESISTANCE WITH USE OF Lenacapavir FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION Individuals must be tested for HIV-1 infection prior to initiating Lenacapavir, and with each subsequent injection of Lenacapavir, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of Lenacapavir by individuals with undiagnosed HIV-1 infection. Do not initiate Lenacapavir unless negative infection status is confirmed. Individuals who acquire HIV-1 while receiving Lenacapavir must transition to a complete HIV-1 treatment regimen . WARNING: RISK OF DRUG RESISTANCE WITH USE OF Lenacapavir FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION See for complete boxed warning.

Common Adverse Reactions and Monitoring

The primary safety assessment of Lenacapavir is based on data from two randomized, double-blind, active-controlled trials, PURPOSE 1 and PURPOSE 2, in which a total of 8616 adult and adolescent participants received Lenacapavir (N=4323), DESCOVY (emtricitabine [FTC]/tenofovir alafenamide [TAF]; N=2135) once daily, or TRUVADA (FTC/tenofovir disoproxil fumarate [TDF]; N=2158) once daily for HIV-1 PrEP. The most commonly reported ISRs (all grades) in at least 2% of participants who received Lenacapavir in either PURPOSE 1 or PURPOSE 2 are presented in Table 7 .

Drug Interactions and Special Populations

( 7 , 12.3 ) 7.1 Effect of Other Drugs on Lenacapavir Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of Lenacapavir. Therefore, dosage modifications (supplemental doses) of Lenacapavir are recommended when initiating strong or moderate CYP3A inducers . Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of Lenacapavir. Concomitant administration of Lenacapavir with these inhibitors is not recommended.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: Yeztugo public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.